Table 1. Demographics of symptomatic patients.
| Without Biomarkers (n = 913) |
With Biomarkers (n = 1617) |
P-Valuea | Wild Type (n = 165) |
Mutant Type (n = 1452) |
Val30Met (n = 1210) |
Non-Val30Met (n = 242) |
P-Valueb | Early Onset (n = 615) |
Late Onset (n = 213) |
P-Valuec | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 379 (41.5%) | 736 (45.5%) | 0.0513 | 8 (4.8%) | 728 (50.1%) | 646 (53.4%) | 82 (33.9%) | <0.0001 | 312 (50.7%) | 94 (44.1%) | 0.0968 |
| Age (years) | 51.0 [36.8, 67.5] | 43.9 [33.0, 64.4] | <0.0001 | 75.3 [71.3, 80.4] | 41.5 [31.9, 57.7] | 37.9 [30.4, 50.9] | 61.4 [52.9, 69.0] | <0.0001 | 37.0 [31.6, 43.8] | 66.9 [60.6, 71.9] | <0.0001 |
| Age at onset of symptoms, (years) | 46.5 [33.1, 61.5] | 41.7 [31.0, 59.4] | 0.0005 | 68.8 [61.8, 75.5] | 38.0 [29.8, 54.5] | 34.8 [28.8, 48.8] | 55.5 [46.1, 64.3] | <0.0001 | 32.2 [27.4, 37.4] | 59.8 [55.0, 65.1] | <0.0001 |
| Cardiac symptoms | 354 (38.8%) | 507 (31.4%) | 0.0002 | 152 (92.1%) | 355 (24.4%) | 215 (17.8%) | 140 (57.9%) | <0.0001 | 126 (20.5%) | 89 (41.8%) | <0.0001 |
| Neurological symptoms | 601 (65.8%) | 1038 (64.2%) | 0.4086 | 86 (52.1%) | 952 (65.6%) | 795 (65.7%) | 157 (64.9%) | 0.8049 | 595 (96.7%) | 200 (93.9%) | 0.0668 |
| mBMI (kg/m2·g/L) | 996 ± 262 | 1078 ± 236 | <0.0001 | 1080 ± 191 | 1077 ± 240 | 1077 ± 235 | 1079 ± 270 | 0.9505 | 1036 ± 232 | 1091 ± 269 | 0.0073 |
| (n = 202) | (n = 1419) | (n = 116) | (n = 1303) | (n = 1140) | (n = 163) | (n = 584) | (n = 185) | ||||
| Karnofsky index (%) | 90 [70, 100] | 90 [80, 100] | <0.0001 | 80 [70, 90] | 90 [80, 100] | 90 [80, 100] | 80 [70, 90] | <0.0001 | 90 [80, 90] | 80 [70, 90] | <0.0001 |
| (n = 677) | (n = 1451) | (n = 106) | (n = 1345) | (n = 1160) | (n = 185) | (n = 592) | (n = 190) | ||||
| eGFR (mL/min/1.73 m2) | 87.4 ± 42.3 | 104.5 ± 120.4 | 0.0165 | 55.7 ± 21.1 | 110.0 ± 125.5 | 112.9 ± 72.0 | 94.4 ± 268.9 | 0.0444 | 109.8 ± 38.5 | 81.7 ± 30.1 | <0.0001 |
| (n = 292) | (n = 1565) | (n = 157) | (n = 1408) | (n = 1186) | (n = 222) | (n = 606) | (n = 198) | ||||
| History of liver transplant | 157 (17.2%) | 249 (15.4%) | 0.2369 | 0 (0%) | 249 (17.1%) | 228 (18.8%) | 21 (8.7%) | 0.0001 | 201 (32.7%) | 22 (10.3%) | <0.0001 |
Data are absolute numbers (percentage), mean ± standard deviation, or median [interquartile range]. Cardiac symptoms are defined as coronary artery disease, dyspnoea, heart failure, myocardial infarction, rhythm disturbances, and syncope. Neurologic symptoms include balance abnormalities, muscle weakness, neuropathic pain/paresthesia, numbness, temperature or pain insensitivity, tingling, walking disability.
ATTR, transthyretin- amyloidosis; eGFR, estimated glomerular filtration rate; mBMI, modified body mass index.
aP-values are With vs. Without Biomarker data
bP-values are Val30Met vs. non-Val30Met.
cP-values are early onset vs. late onset.
The bonferroni corrected p-value adjusting for nine comparisons is 0.005556.